294 related articles for article (PubMed ID: 11328667)
1. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
2. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.
Lee HJ; Engelhardt B; Lesley J; Bickel U; Pardridge WM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1048-52. PubMed ID: 10688622
[TBL] [Abstract][Full Text] [Related]
3. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells.
Kang YS; Voigt K; Bickel U
J Drug Target; 2000; 8(6):425-34. PubMed ID: 11328668
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
5. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
Deguchi Y; Kurihara A; Pardridge WM
Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
7. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.
Lee HJ; Zhang Y; Zhu C; Duff K; Pardridge WM
J Cereb Blood Flow Metab; 2002 Feb; 22(2):223-31. PubMed ID: 11823720
[TBL] [Abstract][Full Text] [Related]
8. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
9. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
Kang YS; Pardridge WM
J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
Wu D; Pardridge WM
J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978
[TBL] [Abstract][Full Text] [Related]
11. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor.
Zhang Y; Pardridge WM
J Pharmacol Exp Ther; 2005 Jun; 313(3):1075-81. PubMed ID: 15718287
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of [3H]biotin bound to different avidin analogues.
Kang YS; Saito Y; Pardridge WM
J Drug Target; 1995; 3(2):159-65. PubMed ID: 7496729
[TBL] [Abstract][Full Text] [Related]
13. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
14. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
[TBL] [Abstract][Full Text] [Related]
15. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.
Wu D; Yang J; Pardridge WM
J Clin Invest; 1997 Oct; 100(7):1804-12. PubMed ID: 9312181
[TBL] [Abstract][Full Text] [Related]
16. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.
Kang YS; Boado RJ; Pardridge WM
Drug Metab Dispos; 1995 Jan; 23(1):55-9. PubMed ID: 7720525
[TBL] [Abstract][Full Text] [Related]
18. Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion.
Alata W; Paris-Robidas S; Emond V; Bourasset F; Calon F
Mol Pharm; 2014 Jan; 11(1):243-53. PubMed ID: 24215184
[TBL] [Abstract][Full Text] [Related]
19. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26.
Aktaş Y; Yemisci M; Andrieux K; Gürsoy RN; Alonso MJ; Fernandez-Megia E; Novoa-Carballal R; Quiñoá E; Riguera R; Sargon MF; Celik HH; Demir AS; Hincal AA; Dalkara T; Capan Y; Couvreur P
Bioconjug Chem; 2005; 16(6):1503-11. PubMed ID: 16287248
[TBL] [Abstract][Full Text] [Related]
20. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate.
Li XB; Liao GS; Shu YY; Tang SX
J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
